Quantum News
Sign InSign Up
Back to News
research

Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Viking Therapeutics reported a Q4 2025 loss of $1.38 per share, missing estimates by $0.48, with zero revenue, though analysts expected none. The earnings call occurred February 11, 2026, led by CEO Brian Lian and CFO Gregory Zante. Management emphasized forward-looking statements under the 1995 Private Securities Litigation Reform Act, warning of risks that could impact future performance. No revenue was generated, aligning with pre-earnings expectations. CEO Brian Lian and CFO Gregory Zante addressed development timelines and milestones, though no specific breakthroughs or setbacks were detailed during the call. Analysts from 12 firms, including JPMorgan and Morgan Stanley, participated, signaling strong institutional interest despite the lack of revenue or profit. The company reiterated its focus on therapeutic development, but no concrete financial or operational updates were provided beyond the earnings miss.
AI Audio Summary
0:00 / 0:00
Click to play
Generate images of quantum computing to be used as banner image for articles (3).jpg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.32K FollowersFollow5ShareSaveCommentsQ4: 2026-02-11 Earnings SummaryInsightsTranscript InsightsPlay CallPlay CallEPS of -$1.38 misses by $0.48 | Revenue of $0.00 beats by $0.00 Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call February 11, 2026 4:30 PM EST Company Participants Brian Lian - President, CEO & DirectorGregory Zante - Chief Financial OfficerNeil Aubuchon - Chief Commercial Officer Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc.Timur Ivannikov - Cantor Fitzgerald & Co., Research DivisionJoon Lee - Truist Securities, Inc., Research DivisionHardik Parikh - JPMorgan Chase & Co, Research DivisionTsan-Yu Hsieh - William Blair & Company L.L.C., Research DivisionWilliam Wood - B. Riley Securities, Inc., Research DivisionJiale Song - Jefferies LLC, Research DivisionAnnabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research DivisionBiren Amin - Piper Sandler & Co., Research DivisionRohit Bhasin - Morgan Stanley, Research DivisionThomas Smith - Leerink Partners LLC, Research DivisionYale Jen - Laidlaw & Company (UK) Ltd., Research DivisionRyan Deschner - Raymond James & Associates, Inc., Research Division Presentation Operator Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 11, 2026. I would now like to turn the call over to Viking's Manager of Investor Relations, Ms. Stephanie Diaz. Please go ahead, Stephanie. Stephanie DiazVida Strategic Partners, Inc. Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, February 11, 2026, will contain forward-looking statements under the safe harbor provisions of the U.S.

Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance.

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.